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Background: Some studies show concentrations of exhaled nitric oxide (FENO) in nonatopic
asthma and in healthy subjects to be similar, but include asthmatics on inhaled steroids, which
is likely to interfere with the results.
Aim: Comparison of FENO between nonatopic asthmatics, low-sensitized and high-sensitized
atopic asthmatics, and healthy controls.
Methods: We studied 85 non-smoking, steroid-naive young men with recently diagnosed
symptomatic asthma and 10 healthy controls. FENO was measured according to European
Respiratory Society Guidelines. In skin prick tests of 13 common aeroallergens, subjects with
a total sum of prick wheals 3e10 mm were regarded as low-sensitized and those with
>10 mm, as high-sensitized. Flowevolume spirometry, standardized histamine challenge,
and an exercise test were also carried out.
Results: Prick tests revealed 14 subjects to be nonatopic and 71 atopic. In high-sensitized subjects
with atopic asthma, the FENOmedian (25e75 quartiles) was significantly higher, 34.9 (21.3e53.8)
parts per billion (ppb), than in subjects with nonatopic asthma, 15.2 (9.7e24.7) ppb (p< 0.001),
both being significantly higher than in healthy controls, 6.6 (5.2e8.5) ppb (p< 0.001). FENO levels
were similar in nonatopic and in low-sensitized atopic asthmatics, with no difference between
them in bronchial responsiveness to histamine and exercise.ital, Sairaalantie 1, PL 500, 06151 Porvoo, Finland. Tel.: þ358 50 5743949; fax: þ358 19 548 2257.
umbus.fi (H. Ekroos).
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Age mean (ran
Height mean (ran
Weight mean (ran
Body mass index mean (ran
FVC % of predb mean (SD)
FEV1% of pred
b mean (SD)
B-eos mean (SD)
Number of positive
reactions
mean (SD)
Mean wheal size mm (SD)
Total atopy score mean (SD)
FVC: forced expiratory vital capacit
a Total prick wheal sum of 3e10 m
b Baseline values (Viljanen et al.).
c Significant difference between nConclusion: Among steroid-naive young male asthmatics, FENO was equally elevated in non-
atopic asthma and in low-sensitized atopic asthma but lower than in those with high-sensitized
atopic asthma. These differences in FENO between asthma groups parallel the differences in
airway function disturbance in terms of responsiveness to histamine or exercise.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Both similarities and differences in the mechanisms of
airway inflammation and in its clinical features occur
between atopic and nonatopic asthma,1 which is charac-
terized by airway inflammation, bronchial hyperrespon-
siveness (BHR) and variable airway obstruction.2
Features of nonatopic asthma are usually greater severity,
female predominance, later onset, and greater steroid
dependence than in atopic asthma.3
Exhaled nitric oxide (FENO) is a useful diagnostic tool, as
it is frequently elevated in asthma, especially in atopic
subjects.4e6 The level of FENO in nonatopic asthmatics has
been similar or slightly higher than in healthy controls.4,5
Some studies have also included asthmatics who are using
inhaled steroids, which can interfere with comparisons.4
The level and type of allergic sensitization affect FENO
values in atopic asthma, with perennial allergens having
the greatest effect.7
BHR to histamine or methacholine is more prominent
in atopic asthma than in nonatopic asthma of similar
severity.8 Associations between FENO and BHR to
histamine or to exercise depend on the atopic status.9 Fur-
thermore, the number of positive skin prick test reactions
seems to correlate positively with exercise-induced asthma
in young athletes,10 and the severity of exercise-induced
bronchoconstriction (EIB) associated with cumulative atopy
score.11 We, therefore, grouped the atopic asthmatics
according to their level of sensitization.subjects.
Healthy subjects
(nZ 10)
No
(n
ge) 19.1 (18e20) 20
ge) 179 (170e188) 17
ge) 74.8 (60e91) 76
ge) 23.3 (18e29) 24
104.2 (13.8) 97
102.4 (12.2) 88
110.0 (37.3) 13
e e
e e
e e
y; FEV1: forced expiratory volume
m, were regarded as low-sensitiz
onatopic and low-sensitization atOur main aim was to compare the FENO of nonatopic
asthmatics with that of both low- and high-sensitized atopic
asthmatics and that of healthy control subjects in a pop-
ulation of steroid-naive, non-smoking male military con-
scripts. The second aim was to compare the characteristics
of airway responsiveness to histamine and exercise with the
type of allergic sensitization.
Methods
Subjects
The 85 study subjects had been referred to the Central
Military Hospital by military physicians from various areas in
Finland because of respiratory symptoms including dysp-
noea, wheezing, cough, sputum production, or symptoms
related to exercise during the 1 month prior to the study.
They were aged 18e27 years, with no history of childhood
asthma, who were recently diagnosed as having asthma
according to American Thoracic Society (ATS) criteria: 12%
reversibility in FEV1 in spirometry, 15% reversibility in PEF
after bronchodilator or 20% daily variability in PEF1 (Table 1).
In Finland, all conscripts are exposed to much outdoor ex-
ercise in the forest and thus have a similar exposure to
allergens (same kind of accommodation, no animal expo-
sure). Conscripts were consecutively included in the study
if they were lifelong non-smokers, had used no inhaled or
oral steroids or chromones during the preceding 2 months,
and had no evidence of respiratory infections within thenatopic asthma
Z 14)
Atopic asthma
low-sensitizationa
(nZ 13)
Atopic asthma
high-sensitizationa
(nZ 58)
.4 (18e26) 20.3 (18e26) 19.9 (18e27)
7 (170e183) 176 (162e191) 175 (160e191)
.0 (49e101) 69.7 (56e82) 76.5 (56e129)
.2 (17e31) 22.3 (21e23) 23.8 (19e31)
.5 (7.6) 102.7 (10.1) 102.1 (12.2)
.5 (6.7) 94.7 (8.6)c 93.7 (9.6)
5.1 (91.7) 255.1 (274.1) 234.5 (146.3)
1.5 (0.5) 5.8 (2.0)
4.3 (1.9) 6.0 (1.6)
6.23 (2.7) 35.0 (17.0)
in 1 s; and B-eos: blood eosinophils.
ed, and those with >10 mm as high-sensitized.
opic asthma; p< 0.05.
154 H. Ekroos et al.preceding 3 weeks. Inclusion criteria for forced expiratory
volume in 1 s (FEV1) was >70% of predicted. Use of inhaled
short-acting beta-agonists was not allowed later than 12 h
before the FENO and lung function measurements. In
addition, 10 non-smoking, nonatopic healthy conscripts,
who were hospitalized for non-respiratory reasons, volun-
teered to become our control group (Table 1).
Study design
On the first study day, flowevolume spirometry, a broncho-
dilatation test, and skin prick tests were carried out, and on
the second day, an exercise challenge was performed.
FENO was measured at 7e8 a.m. on the third study day. The
histamine challenge test was performed immediately after
the FENO determination. No study measurements were
performed during pollen season. This study was approved
by the Ethics Committees of the Department of Medicine at
Helsinki University Hospital and the Central Military Hospi-
tal. Each participant gave his written informed consent.
Spirometry
FEV1, forced vital capacity (FVC), and the FEV1/FVC ratio
were determined with a flowevolume spirometer (Medikro
M904, Kuopio, Finland) according to the European Respira-
tory Society guidelines,12 with Finnish reference values for
spirometry.13
Skin prick tests
Skin prick tests for assessment of atopy were performed
with 13 common aeroallergens: alder, birch, cocksfoot,
timothy, mugwort, horse, dog, cat, sheep’s wool, house
dust mite (Dermatophagoides farinae and Dermatopha-
goides pteronyssinus), Alternaria, and Cladosporium, with
a solvent (glycerin) as the negative and histamine as the
positive control. A wheal with a diameter of at least
3 mm in the presence of expected reactions to the control
solutions was regarded as positive, and subjects with at
least one positive reaction were regarded as atopic. Total
prick wheal sum was calculated by adding the diameters
of the wheals of each positive reaction excluding
histamine.14 Subjects with a total prick wheal sum of
3e10 mm, were regarded as low-sensitized, and those
with >10 mm were regarded as high-sensitized. Mean wheal
size, number of positive responses, and type of sensitiza-
tion were also analyzed.
Histamine challenge
BHR was assessed by histamine challenge with a dosimetric
method and controlled tidal breathing.15 A provocative
dose of histamine inducing a 15% decrease in FEV1
(PD15FEV1) was calculated from the logarithmically trans-
formed histamine doses by linear interpolation. The degree
of bronchial hyperresponsiveness was classified with
PD15FEV1 values. PD15FEV1 less than 0.1 mg was considered
high, PD15FEV1 between 0.1 and 0.4 mg as moderate and
PD15FEV1 between 0.4 and 1.6 mg as mild, respectively.Exercise challenge
A standardized 8-minute test of running was performed by
a previously described method16 outdoors on a 150-meter
circular track between 9 and 11 a.m. Running speed was
adjusted by monitoring each subject’s heart rate with
a Sport Tester PE 3000 heart rate meter (Polar Electro
KY, Kempele, Finland). Subjects raised their heart rate to
85% of their predicted maximal rate, during a 2-minute
warm-up, and maintained this rate (165e175 beats/min)
for the remaining 6 min of the exercise. PEF values were
measured just before the exercise and immediately and 5,
10, 20, and 30 min afterwards of three PEF measurements
on each occasion, the highest value was recorded for analy-
sis. The response to the exercise challenge was the
maximum percentage fall in PEF (6PEF%) after exercise.
Measurement of FENO
FENO was measured as previously described17 with
a chemiluminescence analyzer (Sievers 270B, Boulder, CO,
USA). Expiratory airflow and exhaled volume were
measured with pneumotachograph simultaneously with
FENO in real time, an exhalation procedure performed
according to European Guidelines on exhaled NO measure-
ment.18 Before the measurement, patients rinsed their
mouths with sodium bicarbonate solution to eliminate any
nitric oxide (NO) eventually produced in the mouth. For
measurements of end-expiratory NO, subjects inhaled
100% oxygen (NO-free) and then, without nose-clips,
exhaled slowly from total lung capacity over a period of
15 s. They exhaled against a flow resistor (Hans Rudolph,
Model #7100R, 100 cmH20/L/s, flow range 0e0.5 L/s) to
close the soft palate, thus avoiding any nasal NO contami-
nation. Exhalation flow in the flow window was between
0.08 and 0.15 L/s, and the mean individual exhalation
flow ranged between 0.09 and 0.12 L/s. The mean value
was recorded for a 3-second period from the end-exhaled
NO plateau. For at least three successive measurements,
the mean value was recorded for analysis. The acceptable
coefficient of variation of a single measurement was less
than 0.15.
Statistical methods
FENO and PD15FEV1 were skewed and log transformed
before analysis to achieve a near normal distribution.
FENO and PD15FEV1 levels were reported as medians and
25e75% quartiles, and the other parameters as means
(SD). Differences between anthropometric data, FENO,
PD15FEV1, and severity of EIB in the high-sensitized and
low-sensitized atopic and nonatopic patients and healthy
controls were analyzed with ANOVA. ANOVA tests were
continued with Dunnett’s test based on two hypotheses:
In the first, healthy subjects served as the reference group.
In the second hypothesis, the high-sensitized atopic asthma
group served as the reference group. A separate compari-
son was between those with nonatopic asthma and low-
sensitized atopic asthma.
Multiple linear regression analysis was undertaken using
log (FENO) value as the outcome variable. The model
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FENO concentrations in asthmatics 155evaluated the severity of EIB (6PEF%), log (PD15FEV1),
B-eosinophils, atopy score, seasonal vs perennial sensitiza-
tion, number of positive prick reactions, and size of each
prick reaction with a stepwise method for atopic patients.
Variables in the model were excluded in a stepwise fashion
if they did not reach significance at the 5% level.
All tests were 2-tailed, with a p-value of less than 0.05
considered significant. All analyses were performed with
SPSS version 15.0 (SPSS, Chicago, IL, USA).
Results
Of the 85 subjects, the vast majority, 71 were atopic, and
of these 58 (82%) were high-sensitized (total prick wheal
sum >10 mm) and 13 (18%) low-sensitized (total prick wheal
sum 3e10 mm). Sensitization to perennial allergens was
present in 89% of the high-sensitized and 62% of the low-
sensitized subjects. For these four groups, see Table 1
with patient characteristics, basic pulmonary function,
and differences in atopic status, and Table 2 and Fig. 1
with FENO levels and degree of BHR. The median for
FENO in the high-sensitized atopic patients was more than
double than that in the nonatopic asthmatics. Low-
sensitized and nonatopic asthmatics had similar FENO
levels. Elevated levels (FENO> 12 ppb)18,17 appeared in
57% of subjects with nonatopic asthma, whereas this level
was exceeded by 71% of subjects with low- and 91% with
high-sensitized atopic asthma.
FEV1 of predicted value was slightly higher in low-sen-
sitized atopic asthma subjects than in those with nona-
topic asthma (Table 1). BHR to histamine and to
exercise between subjects with nonatopic asthma and
with low-sensitized atopic asthma were similar, but
high-sensitized atopic asthmatics had significantly more
severe BHR to both histamine and exercise than did those
in nonatopic asthmatics (p< 0.05, both comparisons)
(Table 2).
Linear regression analysis showed that perennial sensi-
tization to cat, severity of EIB and blood eosinophils were
the only significant determinants of FENO in atopic asth-
matics (Table 3).
Discussion
Higher levels of FENO appeared in our nonatopic
asthmatics than in healthy controls. Levels of FENO and
BHR to histamine and to exercise in nonatopic asthmatics
and low-sensitized atopic asthmatics were similar, but
high-sensitized atopic asthmatics showed more severe BHR
to both exercise and histamine and showed higher levels of
FENO than did those in nonatopic and low-sensitized
atopic asthmatics. In atopic asthmatics, the most impor-
tant determinants of FENO were perennial sensitization to
cat, severity of EIB and blood eosinophils.
Our study subjects were ideal for evaluating the associ-
ation of atopy with FENO and BHR in asthma: symptomatic
and steroid-naive young non-smoking men with a recent
diagnosis of asthma but without any interfering diseases.
The skin prick tests included the most important allergens
in Finland.19 The elevated FENO in 57% of our nonatopic
asthmatics is consistent with earlier findings on the
Table 3 Multiple linear regression model with log (FENO)
as dependent variable and severity of EIB (6PEF%), log
(PD15FEV1), B-eosinophils, atopy score, perennial sensitiza-
tion, number of positive prick reactions, and each prick
reaction with stepwise method in atopic patients (nZ 71).
Variable B p-value Partial
correlation
Severity of EIB (6PEF%) 0.023 0.044 0.342
Log (PD15FEV1) 0.0251 0.05 0.254
B-eos 0.001 0.049 0.231
Atopy score 0.156 0.202 0.167
Perennial sensitization 0.239 0.049 0.255
Number of positive
prick reactions
0.188 0.123 0.201
Birch 0.096 0.434 0.103
Alder 0.043 0.725 0.1504
Cocksfoot 0.142 0.253 0.15
Timothy 0.150 0.22 0.161
Mugwort 0.022 0.856 0.024
Horse 0.097 0.446 0.1
Dog 0.124 0.31 0.133
Cat 0.250 0.039 0.267
Sheep’s wool 0.234 0.053 0.251
Dermatophagoides
farinae
0.078 0.488 0.083
Dermatophagoides
pteronyssinus
0.191 0.092 0.2
Alternaria alternata 0.038 0.732 0.041
Cladosporium herbarum 0.107 0.34 0.114
EIB: exercise-induced bronchoconstriction; 6PEF%: maximum
percentage fall in PEF after exercise challenge; PD15FEV1: pro-
vocative dose of histamine causing a 15% fall in FEV1; B: regres-
sion coefficient, and Partial correlation: correlation between
dependent and each independent variable taking into account
the other variables in the model.
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Figure 1 Boxplot presentation of the distribution of exhaled
nitric oxide (FENO) in the groups (outliers are circles and
extreme values are asterisks).
156 H. Ekroos et al.association of FENO level with asthma, irrespective of at-
opy,20 and with a decrease in FENO in nonatopic asthmatics
after treatment with inhaled steroids.21 In contrast, Lud-
viksdottir and coworkers found similar FENO levels in nona-
topic and atopic asthma, but the majority of their patients
were on inhaled steroids.4 In contrast with our results FENO
levels have been similar in steroid-naive nonatopic asthma,
nonatopic rhinitis, and in nonatopic healthy subjects, which
can in part explain the very stable or mild asthma during
study.5
Our study confirms earlier findings that the FENO level is
higher in atopic asthma than in nonatopic asthma.7 The
mechanisms for this are still obscure. One study of bron-
chial biopsies has shown that the number of T-lymphocytes
and interleukin-4 (IL-4) positive cells in bronchial biopsies
of atopic asthmatics are higher than in nonatopic asth-
matics,2 furthermore, IL-4 is one of the most important cy-
tokines inducing FENO production in asthmatic airways.
Moreover, a study by Chistodoupoulos and coworkers has
shown an increased number of a-IL-4R mRNA-positive cells
in atopic asthmatic subjects compared to nonatopic asth-
matics.22 T-lymphocytes and eosinophils thus may probably
be more highly activated and may produce more cytokines
in atopic asthma than in nonatopic asthma, which may ac-
count for the differing levels of FENO in nonatopic and
atopic asthma. Our finding showed blood eosinophils to be
one determinant of FENO both in atopic and nonatopic asth-
matics. The similar FENO in nonatopic and low-sensitized
atopic asthma probably reflects a similar low level of eosin-
ophilic airway inflammation, even though the level of blood
eosinophils is not similar, whereas the high eosinophilic
bronchial inflammation may be more marked in the high-
sensitized group.23
Linear regression analysis showed, moreover, that in
atopic asthmatic patients, the severity of EIB and number
of blood eosinophils, and also sensitization to cats were the
most important determinants of FENO. Our results are
consistent with those of Olin and coworkers showing that
being sensitized to perennial allergens in asthma raised thelevel of FENO compared to asthmatic patients’ sensitization
to seasonal allergens and to that of nonatopic asthmatics.7
Moreover, atopic subjects sensitized only to house dust
mite (HDM), independently of having asthma or not, had
an increased level of FENO.24 Furthermore, levels of FENO
have been significantly higher in patients with asthma
who were both sensitized and exposed to relevant allergen
than in those who were sensitized but not exposed. FENO
thus may be a marker of the airway inflammation induced
by domestic exposure to allergens in sensitized asth-
matics.25 Sensitization to perennial allergens (e.g., cat
and HDM) has also led to increase levels of FENO in asthma.8
In atopic children, elevated FENO was associated with sen-
sitization to perennial allergens, but not to seasonal aller-
gens such as grass pollen. Furthermore, an increase in
FENO was associated with BHR and current wheezing, sug-
gesting that FENO was more than just a marker for atopy.26
In Finland HDM is not a major allergen because of central
heating and dry indoor air, while cats produce the most im-
portant perennial allergen, especially for younger adults.19
To the best of our knowledge, this is the first study
showing that steroid-naive nonatopic asthmatics and low-
sensitized atopic asthmatics have similar levels of FENO as
well as BHR both to histamine and to exercise. Similar
FENO concentrations in asthmatics 157exposure to relevant allergens during military service (same
kind of accommodation, no animal exposure) may contrib-
ute. All study subjects had asthmatic symptoms during the
previous month, which in atopic patients was found to be
associated with FENO on population study.27 In atopic
patients sensitization to cats was strongly associated with
FENO. Few (nZ 2) subjects were sensitized to cats among
the low-sensitized asthmatics, which also explain their
FENO being similar to that of the nonatopics. The mean
number of positive responses in skin prick tests was 5.7 in
those high-sensitized and 1.4 in those low-sensitized,
making contact with relevant allergens more likely for
those high-sensitized. Furthermore, the mean size of the
skin prick test response was clearly smaller in low-
sensitized than in high-sensitized subjects, which also
reflects the higher atopic tendency of the latter. The size
of the skin prick test wheal correlates with the likelihood
of clinical symptoms from that allergen.28
Our finding that the level of BHR to histamine and exercise
is lower in nonatopic asthma than in high-sensitized atopic
asthma is consistent with previous findings.29 Furthermore,
asthmatics sensitized and then exposed to high levels of
sensitizing allergens had lower baseline FEV1 andmore severe
BHR than did asthmatics not sensitized and exposed to
relevant allergens.8 Schwartz and coworkers showed in
a population study that BHR to methacholine increased with
number of positive skin prick tests.30 In one retrospective
study in asthmatics, skin prick reactivity to aeroallergens
was also associated with BHR to methacholine.31 Further-
more, Rouhos and coworkers showed that among steroid-
naı¨ve patients with suspected asthma, only atopics showed
a marked association between FENO and severity of exercise-
or histamine-induced bronchoconstriction.9 In our study, the
degree of atopywas significantwhere BHR to an indirect stim-
ulus was concerned: The magnitude of EIB was higher in high-
sensitized atopic asthmatics than in nonatopic asthmatics.
Similarly, the reactivity to AMP has been higher in atopic
than in nonatopic asthmatics.32 Differences in BHR between
these groups may be explained by the recent finding that
accumulation of mast cells in the smooth muscle compart-
ment ismore prominent in atopic than in nonatopic asthma.33
Our study indicates that FENO is equally elevated in
nonatopic asthma and in low-sensitized atopic asthma but
lower than in high-sensitized atopic asthma among young
adult conscripts. These differences in FENO between the
asthma groups parallel the differences in airway function
disturbance in terms of responsiveness to histamine or
exercise in steroid-naive non-smoking young men.
Conflict of interest statement
The authors have no conflict of interests.Acknowledgements
The authors want to thank the staff of the Central Military
Hospital and the Laboratory of Clinical Physiology for
excellent assistance. Heikki Ekroos was funded by the
Allergy Research Foundation and the Finnish Society for
Allergology and Immunology.References
1. Amin K, Ludviksdottir D, Janson C, et al. Inflammation and
structural changes in the airways of patients with atopic and
nonatopic asthma. Am J Respir Crit Care Med 2000;162:
2295e301.
2. American Thoracic Society, Medical Section of the American
Lung Association. Standards for the diagnosis and care of
patients with chronic obstructive pulmonary disease (COPD)
and asthma. Am Rev Respir Dis 1987;136:225e31.
3. Romanet-Manent S, Charpin D, Magnan A, Lanteaume A,
Vervloet D. EGEA Cooperative Group. Allergic vs nonallergic
asthma: what makes the difference? Allergy 2002;57:607e13.
4. Ludviksdottir D, Janson C, Hogman M, Hedenstrom H,
Bjornsson E, Boman G. Exhaled nitric oxide and its relationship
to airway responsiveness and atopy in asthma. Respir Med
1999;93:552e6.
5. Gratziou C, Lignos M, Dassiou M, Roussos C. Influence of atopy
on exhaled nitric oxide in patients with stable asthma and
rhinitis. Eur Respir J 1999;14:897e901.
6. Dupont LJ, Demedts MG, Verleden GM. Prospective evaluation
of the validity of exhaled nitric oxide for the diagnosis of
asthma. Chest 2003;123:751e6.
7. Olin AC, Alving K, Toren K. Exhaled nitric oxide: relation to
sensitized and respiratory symptoms. Clin Exp Allergy 2004;
34:221e6.
8. Langley S, Goldthorpe S, Craven M, Morris J, Woodcock A,
Custovic A. Exposure and sensitized to indoor allergens:
associations with lung function, bronchial reactivity, and
exhaled nitric oxide measures in asthma. J Allergy Clin
Immunol 2003;112:362e8.
9. Rouhos A, Ekroos H, Karjalainen J, Sarna S, Sovija¨rvi ARA.
Exhaled nitric oxide and exercise-induced bronchoconstriction:
association only in atopics. Allergy 2005;60:1493e8.
10. Helenius IJ, Tikkanen HO, Haahtela T. Occurrence of exercise-
induced bronchospasm in elite runners: dependence on atopy
and exposure to cold air and pollen. Br J Sports Med 1998;
32:25e9.
11. Koh YI, Choi IS, Lim H. Atopy may be related to exercise-
induced bronchospasm in asthma. Clin Exp Allergy 2002;
32:532e6.
12. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R,
Yernault JC. Lung volumes and forced ventilatory flows. Report
Working Party Standardization of Lung Function Tests, Euro-
pean Community for Steel and Coal. Official Statement of
the European Respiratory Society. Eur Respir J 1993;
16(Suppl.):5e40.
13. Viljanen AA, Halttunen PK, Kraus K-E, Viljanen BC. Spirometric
studies in non-smoking, healthy adults. Scand J Clin Lab Invest
1982;42(Suppl. 159):5e20.
14. Miles J, Cayton R, Ayres J. Atopic status in patients with brittle
and non-brittle asthma: a caseecontrol study. Clin Exp Allergy
1995;25:1074e82.
15. Sovija¨rvi ARA, Malmberg LM, Reinikainen K, Rytila¨ P, Poppius H.
A rapid dosimetric method with controlled tidal breathing for
histamine challenge. Chest 1993;104:164e70.
16. Karjalainen J. Exercise response in 404 young men with
asthma: no evidence for a late asthmatic reaction. Thorax
1991;46:100e4.
17. Ekroos H, Tuominen J, Sovija¨rvi ARA. Exhaled nitric oxide and
its long-term variation in healthy non-smoking subjects. Clin
Physiol 2000;20:434e9.
18. Kharitonov SA, Alving K, Barnes PJ. Exhaled and nasal nitric
oxide measurements: recommendations. Eur Respir J 1997;
10:1683e93.
19. Pallasaho P, Ro¨nmark E, Haahtela T, Sovija¨rvi AR, Lundba¨ck B.
Degree and clinical relevance of sensitized to common
158 H. Ekroos et al.allergens among adults: a population study in Helsinki, Finland.
Clin Exp Allergy 2006;36(4):503e9.
20. Malmberg LP, Turpeinen H, Rytila P, Sarna S, Haahtela T. Deter-
minants of increased exhaled nitric oxide in patients with sus-
pected asthma. Allergy 2005;60:464e8.
21. Dal Negro R, Micheletto C, Tognella S, Turco P, Rossetti A,
Cantini L. Assessment of inhaled BDP-dose dependency of ex-
haled nitric oxide and local and serum eosinophilic markers in
steroid-naı¨ve nonatopic asthmatics. Allergy 2003;58:1018e22.
22. Chistodoupoulos P, Cameron L, Nakamura Y, et al. TH2 cyto-
kine-associated transcription factors in atopic and nonatopic
asthma: evidence for differential signal transducer and activa-
tor of transcription 6 expression. J Allergy Clin Immunol 2001;
107:586e91.
23. Rytila P. Induced sputum for assessment of airway inflammation in
patients with COPD, asthma and asthma-like symptoms. Disserta-
tion, Helsinki University, Finland. 2002. http://ethesis.helsinki.fi/
julkaisut/laa/kliin/vk/rytila/induceds.pdf.
24. Barreto M, Villa MP, Martella S, et al. Exhaled nitric oxide in asth-
matic and non-asthmatic children: influence of type of allergen
sensitized and exposure to tobacco smoke. Pediatr Allergy Immu-
nol 2001;12:247e56.
25. Simpson A, Custovic A, Pipis S, Adisesh A, Faragher B,
Woodcock A. Exhaled nitric oxide, sensitized, and exposure
to allergens in patients with asthma who are not taking inhaled
steroids. Am J Respir Crit Care Med 1999;160:45e9.
26. Leuppi JD, Downs SH, Downie SR, Marks GB, Salome CM.
Exhaled nitric oxide levels in atopic children: relation tospecific allergic sensitisation, AHR, and respiratory symptoms.
Thorax 2002;57:518e23.
27. Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Tore´n K.
Height, age, and atopy are associated with fraction of exhaled
nitric oxide in a large adult general population sample. Chest
2006;130:1319e25.
28. Sears MR, Burrows B, Flannery EM, Herbison GP, Holdaway MD.
Atopy in childhood. I. Gender and allergen related risks for devel-
opmentofhay feverandasthma.ClinExpAllergy1993;23:941e8.
29. Obase Y, Shimoda T, Mitsuta K, Matsuo N, Matsuse H,
Kohno S. Sensitivity to the house dust mite and airway hyper-
responsiveness in a young adult population. Ann Allergy
Asthma Immunol 1999;83:305e10.
30. Schwartz J, Schindler C, Zemp E, et al. Predictors of metha-
choline responsiveness in a general population. Chest 2002;
122:812e20.
31. Fowler SJ, Lipworth BJ. Relationship of skin prick reactivity to
aeroallergens and hyperresponsiveness to challenges with
methacholine and adenosine monophosphate. Allergy 2003;
58:46e52.
32. Ludviksdottir D, Janson C, Bjo¨rnsson E, et al. Different airway
responsiveness profiles in atopic asthma, nonatopic
asthma and Sjo¨gren’s syndrome. Allergy 2000;55:
259e65.
33. Amin K, Janson C, Boman G, Venge P. The extracellular
deposition of mast cell products is increased in hypertrophic
airways smooth muscles in allergic asthma but not in nonaller-
gic asthma. Allergy 2005;60:1241e7.
